Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : THX-160
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : The University of Calgary
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : THX-160
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : The University of Calgary
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Evero
Deal Size : Undisclosed
Deal Type : Partnership
Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication
Details : As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Evero
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
